Food refusal is a hallmark of exposure of experimental animals to the trichothecene mycotoxin deoxynivalenol (DON), a common foodborne contaminant. Although studies in the mouse suggest that DON suppresses food intake by aberrantly inducing the release of satiety hormones from enteroendocrine cells (EECs) found in the gut epithelium, the underlying mechanisms for this effect are not understood. To address this gap, we employed the murine neuroendocrine tumor STC-1 cell line, a widely used EEC model, to test the hypothesis that DON-induced hormone exocytosis is mediated by G proteincoupled receptor (GPCR)-mediated Ca 2þ signaling. The results indicate for the first time that DON elicits Ca 2 -dependent secretion of cholecystokinin (CCK) and glucagon-like peptide-1 7-36 amide (GLP-1), hormones that regulate food intake and energy homeostasis and that are products of 2 critical EEC populations-I cells of the small intestine and L cells of the large intestine, respectively. Furthermore, these effects were mediated by the GPCR Ca 2þ -sensing receptor (CaSR) and involved the following serial events: (1)PLC-mediated activation of the IP3 receptor and mobilization of intracellular Ca 2þ stores, 
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-dependent secretion of cholecystokinin (CCK) and glucagon-like peptide-1 7-36 amide (GLP-1), hormones that regulate food intake and energy homeostasis and that are products of 2 critical EEC populations-I cells of the small intestine and L cells of the large intestine, respectively. Furthermore, these effects were mediated by the GPCR Ca 2þ -sensing receptor (CaSR) and involved the following serial events: (1)PLC-mediated activation of the IP3 receptor and mobilization of intracellular Ca 2þ stores, ankyrin-1 channel activation, and finally (4) Ca 2þ -driven CCK and GLP-1 excytosis. These in vitro findings provide a foundation for future investigation of mechanisms by which DON and other trichothecenes modulate EEC function in ex vivo and in vivo models.
Appetite and food intake are normally controlled by both central and peripheral factors that influence the balance of anor exigenic and orexigenic signaling in the brain (Schwartz, 2006) . In the mouse, oral exposure to DON rapidly upregulates the expression of specific components of the anorexigenic response in hypothalamic neurons of the brain, including the pro-opiomelanocortin (POMC), melanocortin 4 receptor (MC4R), and cocaine amphetamine-regulated transcript (Girardet et al., 2011a,b) . A potential upstream mechanism for elevated expression of these hypothalamic anorexigenic hormones is increased secretion of the gut satiety peptides by enteroendocrine cells (EEC) of the gastrointestinal (GI) tract (Moran-Ramos et al., 2012; Steinert et al., 2013) .
The EEC is a primary intestinal cell subtype that, along with enterocytes, goblet, and Paneth cells derived from intestinal stem cells populates the epithelial layer of the GI tract (Moran-Ramos et al., 2012) . Although EECs comprise only $1% of all gut epithelial cells, as a whole they represent one of the largest endocrine organs in the body, making them a central target for toxins entering the gut. At least 15 regionally associated EEC lineages have been described that are generated from a common neurogenin3-positive secretory progenitor population. A paramount function of EECs is to sense nutrients of the gut lumen and respond by secreting a range of peptide and amine hormones. These hormones control numerous digestive and physiologic functions, including food intake, postmeal gastric secretion, gut motility, energy expenditure, and maintenance of glucose levels by acting peripherally on adjacent cells and afferent enteric neurons and/or on distal cells of the central nervous system (Gribble, 2012; Reimann et al., 2012; Tolhurst et al., 2012) .
Cholecystokinin (CCK), peptide YY 3-36 , and glucagon-like peptide-1 7-36 amide (GLP-1) are examples of satiety hormones secreted by EEC. CCK is produced by I cells, an EEC population found in the jejunum and ileum, that elicits shortterm, diminished food consumption by upregulating POMC and MC4R expression (Dockray, 2009) . Both peripheral and central administration of CCK to animals causes decreased food consumption. PYY 3-36 is produced by L-cells, an EEC population that populates the lower GI tract including the distal ileum and colon (Karra and Batterham, 2010) . This hormone both upregulates anorexigenic and downregulates orexigenic signaling molecules within the brain, inducing satiety in many species including humans, nonhuman primates, and rodents. GLP-1 is another hormone of L-cell origin that is secreted in response to a meal and evokes satiety (Williams et al., 2009) . Several recent investigations by our laboratory support the contention that EEC-derived gut satiety hormones contribute to DON's anorectic effects in mice. Importantly, both oral and IP administration of DON in mice dose-dependently induces rapid ( 15 min) elevations in plasma CCK and PYY 3-36 with concurrent food refusal (Flannery et al., 2012; Wu et al., 2014) . Subsequent experiments with specific pharmacologic antagonists to CCK and PYY receptors attenuate this effect, thus further indicating that these hormones are upstream mediators of DON-induced anorexigenic signaling in the hypothalamus.
Although in vivo studies have established that DON suppresses food intake by inducing the aberrant release of hormones originating from EEC, the upstream mechanisms for this effect are not understood. Recent investigations have demonstrated that a variety of G protein-coupled receptors (GPCRs) are present in EEC that function as chemosensors of the gut luminal content (Liou ,2013; Reimann et al., 2012) . The goal of this research study was to test the hypothesis that DON induces hormone exocytosis in EEC by GPCR-mediated Ca 2þ signaling.
To achieve this goal, we employed a widely used EEC model, the murine neuroendocrine tumor STC-1 cell (Hira et al., 2008; Kurogi et al., 2012; Shah et al., 2012) , that exhibits characteristics of both duodenal I-cells (ie, secretes CCK) and ileal-colonic Lcells (ie, secretes GLP-1) (Geraedts et al., 2011) . Our primary focus was to determine DON's short-term (15-45 min) effects (ie, intracellular calcium increase and hormone secretion) in this enteroendocrine model that would be indicative of an intestinal chemical defense response (eg, food refusal) observed in vivo in the mouse (Flannery et al., 2012; Wu et al., 2014) . The results suggest that DON induces secretion of both hormones from STC-1 by activating the GPCR calcium-sensing receptor (CaSR) as well as a unique downstream pathway involving transient receptor potential melastatin-5 ion channel (TRPM-5) and transient receptor potential ankyrin-1 (TRPA1). RT-PCR analysis for TRPM5, TRPA1, and CaSR mRNA. Total RNA was purified from adherent monolayer of STC-1 cells in a 6-well culture plate with TRI Reagent solution (Life Technologies). RNA was subjected to reverse transcription with High Capacity RNA to cDNA Kit (Life Technologies) and purified with QIA quick PCR Purification Kit (Qiagen, Valencia, California). Resultant firststrand cDNA was used as a template for PCR. The following mouse-specific primer pairs were used: TRPM5: 5 Western blot analysis for TRPM5, CaSR, and TRPA1. Total proteins were extracted from adherent monolayers of STC-1 cells in a 100 mm culture plate by adding boiling lysis buffer consisting of 1% (w/v) SDS, 1 mM sodium orthovanadate and 10 mM Tris (pH 7.4). Cells were boiled in lysis buffer for 5 min, sonicated briefly and then centrifuged at 12 000 Â g for 10 min at 4 C. The protein concentration of the resultant supernatant was determined with a BCA Protein Assay Kit (Thermo Scientific, Rockford, Illinois). Samples (40 mg protein) were resolved on a precast 4%-20% (w/v) polyacrylamide gel (Bio-Rad, Hercules, California) and the proteins were transferred to an Immobilon-FL membrane (Millipore, Billerica, Massachusetts). After blocking with Odyssey Blocking buffer (LI-COR, Lincoln, Nebraska) for 1 h at 25 C, membranes were incubated overnight at 4 C in LI-COR blocking buffer with goat polyclonal anti-TRPM5 (1:10 000) (NBP1-44059, Novus, Littleton, Colorado); rabbit polyclonal antiCaSR of mouse, rat, and human origin (NBP1-19452, Novus) (1:1000) or rabbit polyclonal anti-TRPA1 (AB68847,Abcam, Cambridge, Massachusetts) (1:10 000). Blots were washed 3 times of 10 min with TBST buffer (50 mM Tris, 150 mM NaCl and 0.1% [v/v] Tween 20, PH7.5) and then incubated in blocking buffer containing either IRDye 800CM donkey anti-goat IgG (H þ L) (LI-COR) (1:20 000) for TRPM5 or IRDye 800CW goat anti-mouse IgG (H þ L) secondary antibody (LI-COR) (1:3000 for CaSR or 1:20 000 for TRPA1). Infrared fluorescence intensity was detected on the Odyssey Infrared Imaging System (LI-COR). 
MATERIALS AND METHODS

RESULTS
DON Induces CCK and GLP-1 Release in STC-1 Cells via Ca2
1 -Mediated Signaling Exposure of STC-1 cells to DON from 0.5 to 5 mM induced the secretion of CCK (Fig. 1A) and GLP1 (Fig. 1B) in a concentrationdependent fashion after 45 min. When the effects of different DON concentrations over the same time period on the MTT response were determined, viabilities were 100% 6 11.4%, 108% 6 9.6%, 94% 6 11.8%, and 80% 6 10.3% for DON 0, 1, 2, or 5 mM, respectively ( Supplementary Fig. S1 ). When the effects of 2 mM DON were measured over a 90-min time period, secretion of both hormones was evident as early as 15 min in cells treated with ( Fig. 1C and 1D ). STC-1 viability was unaffected by 2 mM DON up to 45 min but was decreased by $10% at 60 and 90 min ( Supplementary Fig. S1 and Table S1 ). Based on these findings, subsequent treatments employed 2 mM DON and were incubated for 45 min.
The potential role of Ca 2þ in DON-induced hormone secretion by the STC-1 cell line was assessed using selective antagonists. The PLC inhibitor U73122 and IP3 receptor antagonist 2-APB suppressed CCK secretion suggesting PLC-dependent release of Ca 2þ stores were involved in release of this hormone ( Fig. 2A) . In addition, the TRPM5 Na 2þ channel inhibitor TPPO, the L-type VSCC inhibitor nitrendipine and the extracellular Ca 2þ chelator EGTA all inhibited DON-induced CCK release indicating possible involvement of extracellular Ca 2þ entry. DONinduced GLP-1 secretion similarly involved these Ca 2þ -dependent mechanisms (Fig. 2B) . STC-1 cell expression of TRPM5 mRNA and protein was demonstrated by PCR ( Fig. 2C ) and Western analysis (Fig. 2D) , respectively, confirming that this channel was expressed in this EEC model.
DON-Induced Intracellular Calcium Increase Requires the GPCR CaSR
As suggested by the antagonist studies, confocal microcopy studies revealed that DON induced rapid (1-2 min) elevation of [Ca 2þ ] i in STC-1 cells but not in control HEK 293 cells at concentrations that were consistent with hormone secretion (Fig. 3A) . Furthermore, [Ca 2þ ] i elevation was dependent on the presence of extracellular Ca 2þ ( Fig. 3B and 3C) , which suggested the possible involvement of CaSR, a GPCR previously reported to be present on STC-1 (Hira et al., 2008) . Expression of CaSR by the STC-1 line was demonstrated by RT-PCR (Fig. 4A ), Western analysis (Fig. 4B ) and immunocytochemistry (Fig. 4C) . Exposure of STC-1 cells to the allosteric CaSR agonist NPS 568 elicited a rapid increase in [Ca 2þ ] i that was ablated by preincubation with the allosteric antagonist NPS 2143 (Fig. 4D) . Preincubation with CaSR antagonists NPS 2143 (Fig. 5A ) and Calhex 231 (Fig. 5B) in the cell line was confirmed by PCR ( Fig. 6A) and Western analysis (Fig. 6B) . The functionality of this channel was verified based on the induction of elevated [Ca 2þ ] i by the TRPA1 agonist AITC and the inhibition of this response by the TRPA1 antagonists HC 030031 and A967079 (Fig. 6C) . DON-induced elevation of [Ca 2þ ] i was likewise suppressed in a concentration-dependent manner by the TRPA1 antagonist HC 030031 (Fig. 7) . These data indicate that, in addition to CaSR, TRPA1 appeared to be involved in DON-mediated elevation in [Ca 2þ ] i .
CaSR-Driven [Ca 21 ] i Increase and Hormone Release Requires TRPA1
Induction of [Ca 2þ ] i elevation in STC1 by the CaSR agonist NPS 568 was not only be suppressed by the CaSR antagonist NPS 2143 but also by the TRPA1 antagonists HC0300331 and A 967079 (Fig. 8) . Thus, TRPA1 appeared to play a role downstream to CaSR in eliciting increased cytosolic Ca 2þ in STC-1 cells. The joint contributions of CaSR and TRPA1 in DON-induced hormone secretion were assessed in STC-1 cells using pharmacological antagonists. DON-induced CCK release was suppressed by the CaSR antagonists NPS 2143 and Calhex 231 as well as the TRPA1 antagonist HC 030031 (Fig. 9A-C) . The combination of HC 030031 with either NPS 2143 or Calhex 231 additively inhibited DON-mediated CCK secretion. Similar results were observed relative to DON-induced GLP-1 secretion ( Fig. 9B and 9D ), again suggesting that CaSR and TRPA1 played complementary roles in these responses. CaSR-and TRPA1-Knockdown Impair DON-Induced CCK Release The effects of CaSR-and TRPA1-specific siRNA knockdown on DON-induced CCK exocytosis were evaluated in STC-1 to confirm findings with pharmacologic antagonists. siRNA transfection caused $35% and 45% reductions in CASR mRNA (Fig. 10A ) and TRPA1-mRNA (Fig. 10B) expression levels, respectively, as compared with the vehicle-transfected cells. Transfections with CaSR siRNAs (Fig. 10C) or with TRPA1 siRNAs (Fig. 10D) significantly attenuated DON-stimulated CCK release in STC-1 cells. Furthermore, DON-induced CCK release was identical in cells transfected with negative control siRNAs to those transfected only with vehicle ( Fig. 10C and 10D) . Thus, siRNA knockdown confirmed the antagonist studies, again suggesting that CaSR and TRPA1 were both involved in DON-induced CCK secretion.
DISCUSSION
Prior investigations in the mouse have suggested that DONinduced food refusal is mediated by hormones known to be produced by EECs (Flannery et al., 2012; Wu et al., 2014) . Here, we employed the murine STC-1 model to elucidate the upstream mechanisms by which DON elicits EEC hormone secretion. The results indicate for the first time that DON induces Ca 2 -dependent secretion of CCK and GLP-1. These hormones regulate food intake and energy homeostasis and are products of 2 critical EEC populations-I cells of the small intestine and L cells of the large intestine, respectively. Although this cell line expresses PYY mRNA, it did not robustly secrete the PYY 3-36 in response to known STC-1 inducers or to DON (data not shown). As summarized in Figure 11 , the data presented herein suggest that DON Consistent with our findings, STC-1 has been previously shown to respond to agonists and antagonists of CaSR, TRPM5, and TRPA1 (Hira et al., 2008; Kurogi et al., 2012; Nakajima et al., 2012; Purhonen et al., 2008; Shah et al., 2012) . CaSR regulates serum calcium homeostasis and is directly activated by sensing increased extracellular Ca 2þ , other inorganic cations and organic polycations; however, this receptor has many other physiological roles (Chakravarti et al., 2012; Ward et al., 2012) . Importantly, it has been postulated that CaSR functions as a chemosensor of intestinal luminal content and that its activation can elicit secretion of gut hormones which regulate nutritional homeostasis (Liou et al., 2011; Nakajima et al., 2012) . Consistent with this role, in the presence of Ca polyamines, and fatty acids that are encountered in the gut after meal consumption. Our results suggest that DON hijacks these normal physiologic processes by acting on CaSR, thereby disrupting homeostasis and causing aberrant loss of appetite. It is possible that the toxin allosterically interacts with CaSR but this will require further study.
TRPM5 is a Ca 2þ -activated cation channel that mediates signaling in taste and other chemosensory cells (Huang and Roper, 2010) . This TRP channel is distributed in chemosensory cells located throughout the digestive tract, in the respiratory system and in the olfactory system (Liman, 2007) . TRPM5 is the final element in a signaling cascade that starts with the activation of GPCRs by bitter, sweet, or umami taste molecules and that requires PLCb2 (Kaske et al., 2007) . Consistent with our model, this latter enzyme catalyzes the conversion of PIP2 into DAG and IP3, and the ensuing release of Ca 2þ from intracellular stores activates TRPM5. It is well known that TRPA1 is expressed in neurons and mediates pain and neurogenic inflammation in response to heat, cold, mechanical, and chemical stressors (Nilius et al., 2012) . However, its expression and role in nonneuronal cell types that control diverse physiological functions is now being recognized as important (Fernandes et al., 2012) . The finding that DON mediates increased [Ca 2þ ] i in part, via TRPA1, was surprising because in its role as a chemosensor, TRPA1 is primarily activated by reactive chemicals such as allyl isothiocyanate (AITC), cinnamaldehyde, formalin, hydrogen peroxide, 4-hydroxynonenal, and acrolein. Although DON contains an epoxide group, this moiety is shielded by the parent ring thus masking and preventing it from reacting with other chemicals or macromolecules. As an alternative, it has been proposed that TRPA1 and other TRP channels are activated through intracellular signaling involving: (1) GPCR-mediated activation via PLC and diacylglycerol (DAG)-dependent mechanisms, (2) intracellular phosphatidylinositol phosphates (eg, PIP 2 ), (3) elevated [Ca 2þ ] I, and (4) membrane depolarization (Nilius et al., 2012) .
Thus, it is reasonable to suggest that TRPA1 activation results from DON-induced CaSR activation (Fig. 11 ) rather than as a result of direct interaction between the toxin and this TRP channel. Nevertheless, a few nonreactive activators (eg, nicotine, PF-4840154) have been reported to activate TRPA1, so without further investigation it is not yet possible to exclude the possibility of a direct interaction with DON. We recognize that a limitation of this study was that the high DON concentrations employed might possibly be associated with other toxic effects upon prolonged incubation (Maresca, 2013) such as apoptosis as has been observed in the RAW 264.7 macrophage cell line incubation with 1 mM DON for 6 h (Zhou et al., 2005) . Because our primary focus was to determine DON's short term (15-45 min) effects (ie, intracellular calcium increase and hormone secretion) in this enteroendocrine model that would be indicative of a rapid intestinal chemical defense response (eg, food refusal, reduced gut motility, and emesis), we confirmed viability during this time period but did not measure the effects on viability of !6 h incubation at these concentrations. Although concentrations of DON required to evoke Ca 2þ and hormone responses in STC-1 (!500 mM) were very similar to those of other agonists that induce hormone secretion in this model (Hira et al., 2008) , comparatively lower DON gut luminal and tissue concentrations (!10 mM) might be expected to elicit satiety hormone elevations and anorectic responses in the mouse (Flannery et al., 2012) . This divergence might reflect several inherent limitations associated with using the cloned STC-1 line to predict the effects of EEC lineages in vivo. First, the dissociated state of these cells and absence of adjacent (ie, epithelial, Paneth, goblet) or supporting cells might affect their ability to respond identically to the in vivo setting. Second, the responsiveness might be affected by the absence of basal luminal components such as nutrients (eg, amino acids, fatty acids) and microbiota found naturally in the gut that might have modulatory effects on EEC. Finally, because STC-1 is a cancer cell line, there is the clear potential for expression of drug transporters such as the ABC and MDR families (Choi and Yu, 2014; Kathawala et al., 2014) which have been demonstrated to affect DON uptake (Videmann et al., 2007) . Nevertheless, the STC-1 model provides a useful starting point for future investigations of GPCR-and TRP-related mechanisms in ex vivo and in vivo models. Taken together, the results of this investigation indicate that DON evokes CCK and GLP-1 secretion in the STC-1 EEC model by activating CaSR-and TRPA1-mediated Ca 2þ signaling pathways (Fig.11) . A potential outcome of this research is that understanding the cellular and molecular mechanisms for DON's anorectic effects will facilitate design of new strategies for preventing these effects in humans and animals as well as lead to new in vitro assays to identify, classify and measure toxic potencies of trichothecene congeners/metabolites that target EEC. The capacity for DON to evoke aberrant secretion of satiety hormones is of further interest because of their recognized pathophysiological involvement in irritable bowel syndrome (Zhang et al., 2008) , eating disorders (Chaudhri et al., 2006) and failure to thrive in the elderly (Hays and Roberts, 2006) . Over the long term, it is anticipated that this research will serve as a template for future exploration into the role of different EEC lineages in sensing foodborne toxins, chemotherapeutic drugs, environmental toxicants, and chemical warfare agents that might elicit anorexia and emesis through analogous GPCR-and TRP-mediated mechanisms.
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